Last updated 9 days ago
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
350 patients around the world
Available in Mexico, Argentina
The study will include a screening period of up to 5 weeks. The primary endpoint will be
at Week 44 with a tirzepatide extension until week 80. A safety follow up will be
performed approximately 4 weeks after end of treatment.
Eli Lilly and Company
10Research sites
350Patients around the world
This study is for people with
Diabetes
Diabetes mellitus type 2
Obesity
Requirements for the patient
To 75 Years
All Gender
Medical requirements
Sites
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Recruiting
Centro Médico Viamonte SRL - CABA, Buenos Aires
Recruiting
CEDIC Centro de Investigación Clínica - CABA, Buenos Aires
Recruiting
Centro Medico Dra. Laura Maffei - Investigación Clínica Aplicada
Recruiting
Consultorio de Investigación Clinica EMO SRL
Recruiting
Centro de Estudios de Investigación Metabólica y Cardiovascular SC
Recruiting
CINCAME (Centro de Investigación Cardiovascular y Metabólica)
Recruiting
Cryptex Investigación Clínica
Recruiting
CEDOPEC Centro Especializado en Diabetes, Obesidad y Enfermedades Cardiovasculares
Recruiting
Virgen Cardiovascular Research S.C
Recruiting
SponsorEli Lilly and Company
Conditions
Diabetes mellitus type 2
Requirements
To 75 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06037252
